Trial Profile
A Phase 2 Study of Fludarabine, Cytarabine, Filgrastim-sndz,Gemtuzumab Ozogamicin and Idarubicin in Newly Diagnosed Core Binding Factor Associated Acute Myelogenous Leukemia
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Dec 2023
Price :
$35
*
At a glance
- Drugs Cytarabine (Primary) ; Decitabine (Primary) ; Filgrastim (Primary) ; Fludarabine (Primary) ; Gemtuzumab ozogamicin (Primary) ; Idarubicin (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 21 Dec 2023 Planned number of patients changed from 200 to 270.
- 13 Oct 2023 Planned End Date changed from 30 Dec 2023 to 30 Dec 2024.
- 13 Oct 2023 Planned primary completion date changed from 30 Dec 2023 to 30 Dec 2024.